These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 46221)

  • 21. [Clinical evaluation of isometric detrusor pressure in patients with benign prostatic hyperplasia].
    Nishimoto K
    Hinyokika Kiyo; 1990 Jan; 36(1):19-26. PubMed ID: 1689929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benign prostatic obstruction and parkinson's disease--should transurethral resection of the prostate be avoided?
    Roth B; Studer UE; Fowler CJ; Kessler TM
    J Urol; 2009 May; 181(5):2209-13. PubMed ID: 19296974
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Medical treatment of prostatic adenoma. Urinary flow data].
    Giglio V; Campo B; Motta M
    Minerva Urol; 1972; 24(3):104-7. PubMed ID: 4141047
    [No Abstract]   [Full Text] [Related]  

  • 24. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
    Te AE; Malloy TR; Stein BS; Ulchaker JC; Nseyo UO; Hai MA
    BJU Int; 2006 Jun; 97(6):1229-33. PubMed ID: 16686717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New methods for the evaluation of cervico-prostatic obstruction].
    Fanciullacci F; Sandri S; Politi P; Zanollo L; Spinelli M
    Arch Ital Urol Nefrol Androl; 1992 Dec; 64(4):325-9. PubMed ID: 1281339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Gallegos PJ; Frazee LA
    Pharmacotherapy; 2008 Mar; 28(3):356-65. PubMed ID: 18294115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A double-blind trial on the effect of bunazosin hydrochloride for the symptoms of benign prostatic hypertrophy].
    Kumamoto Y; Tsukamoto T; Yachiku S; Kaneko S; Koyanagi T; Togashi M; Maru A; Tsuchida S; Nishizawa O; Orikasa S
    Hinyokika Kiyo; 1990 Oct; 36(10):1213-32. PubMed ID: 1702262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of bladder outlet obstruction and detrusor contractility on residual urine in patients with benign prostatic hyperplasia.
    Zhang P; Wu Z; Gao J
    Chin Med J (Engl); 2003 Oct; 116(10):1508-10. PubMed ID: 14570611
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional and anatomical effects of hormonally induced experimental prostate growth: a urodynamic model of benign prostatic hyperplasia (BPH) in the beagle.
    Yokota T; Honda K; Tsuruya Y; Nomiya M; Yamaguchi O; Gotanda K; Constantinou CE
    Prostate; 2004 Feb; 58(2):156-63. PubMed ID: 14716740
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Use of alpha1-adrenergic blockaders in treating voiding disorders after transurethral resection of the prostate].
    Martov AG; Gushchin BL; Oshchepkov VN; Ergakov DV
    Urologiia; 2002; (5 Suppl):23-37. PubMed ID: 12518670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benign prostatic hyperplasia. Does a correlation exist between prostatic morphology and irritative symptoms?
    Atan A; Horn T; Hansen F; Jakobsen H; Hald T
    Scand J Urol Nephrol; 1996 Aug; 30(4):303-6. PubMed ID: 8908653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of alpha-adrenergic blockers in benign prostatic obstruction.
    Caine M; Pfau A; Perlberg S
    Br J Urol; 1976 Aug; 48(4):255-63. PubMed ID: 61054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of urinary retention due to benign prostatic hyperplasia using luteinizing hormone-releasing hormone agonist.
    Schlegel PN; Brendler CB
    Urology; 1989 Aug; 34(2):69-72. PubMed ID: 2474882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Indoramin--an effective new drug in the management of bladder outflow obstruction.
    Iacovou JW; Dunn M
    Br J Urol; 1987 Dec; 60(6):526-8. PubMed ID: 2447995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The use of the alpha 1-adrenoblocker doxazosin in the pharmacotherapy of disorders of urine outflow of spastic origin].
    Ukhal' MI; Malomuzh OI; Strashnyĭ VV; Shumilin MV
    Lik Sprava; 1998 Dec; (8):118-21. PubMed ID: 10204368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conservative treatment of benign prostatic hyperplasia.
    Palanca E; Juco W
    Curr Med Res Opin; 1977; 4(7):513-20. PubMed ID: 66118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute retention of urine due to benign prostatic obstruction treated with alpha-adrenergic blockers.
    Reuther K; Aagaard J
    Urol Int; 1984; 39(2):114-5. PubMed ID: 6202036
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of benign prostatic hyperplasia by phenol injection.
    Angell JC
    Br J Urol; 1969 Dec; 41(6):735-8. PubMed ID: 4188054
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.